Ionis Pharmaceuticals (IONS) Receivables - Other (2017 - 2026)

Ionis Pharmaceuticals' Receivables - Other history runs 10 years deep, the most recent figure standing at $73.7 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 85.57% year-over-year to $73.7 million in Q1 2026; TTM through Mar 2026 was $73.7 million, a 85.57% increase from a year earlier, with the FY2025 full-year figure at $66.1 million, down 28.34% from the prior year.
• Receivables - Other improved to $73.7 million in Q1 2026 per IONS's latest filing, from $66.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $142.4 million in Q3 2023 and bottomed at $5.1 million in Q1 2024.
• The 5-year median for Receivables - Other is $27.3 million (2024), against an average of $43.9 million.
• Across the five-year window, Receivables - Other surged 2042.35% in 2023 and sank 87.41% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $25.5 million in 2022, then jumped by 282.87% to $97.8 million in 2023, then slipped by 5.72% to $92.2 million in 2024, then dropped by 28.34% to $66.1 million in 2025, then rose by 11.54% to $73.7 million in 2026.
• Per Business Quant, the three latest IONS Receivables - Other figures stand at $73.7 million (Q1 2026), $66.1 million (Q4 2025), and $24.6 million (Q3 2025).